Kutoh Eiji, Hayashi Jyunka
Division of Clinical Research, Biomedical Center, Tokyo, Japan.
Division of Diabetes and Endocrinology, Department of Internal Medicine, Gyoda General Hospital, Saitama, Japan.
Drug Res (Stuttg). 2019 May;69(5):297-300. doi: 10.1055/a-0748-5745. Epub 2018 Oct 8.
This report describes the effect of administration (n=3) or withdrawal (n=2) of canagliflozin, a sodium-glucose co-transporters 2 (SGLT-2) inhibitor, on cardiac function in relation to ketone bodies. Three cases received and two cases discontinued canagliflozin. Changes of heart function with ultrasonography (EF: ejection fraction and %FS: functional shortening) and cardiometabolic parameters including ketone bodies (acetoacetate/beta-hydroxybutylate) were compared at 3 months. 69, 68 and 60 years old male patients A, B and C, respectively with moderately decreased heart function received canagliflozin 100 mg/day. EF, %FS and acetoacetate/beta-hydroxybutylate levels increased. 60 and 59 years old female patients D and E with normal and borderline heart function, respectively discontinued canagliflozin 50 mg/day. EF, %FS and acetoacetate/beta-hydroxybutylate levels decreased. Taken together, these results suggest that concomitant changes between ketone bodies and heart function were observed with or without canagliflzoin. This drug might have effects on cardiac function through modulating ketone bodies.
本报告描述了钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂卡格列净的给药（n = 3）或撤药（n = 2）对与酮体相关的心脏功能的影响。3例患者接受了卡格列净治疗，2例患者停用了卡格列净。在3个月时比较了超声心动图检查的心脏功能变化（EF：射血分数和%FS：功能缩短率）以及包括酮体（乙酰乙酸/β-羟基丁酸）在内的心脏代谢参数。69岁、68岁和60岁的男性患者A、B和C，心脏功能均有中度下降，接受了每日100毫克的卡格列净治疗。EF、%FS和乙酰乙酸/β-羟基丁酸水平均升高。60岁和59岁的女性患者D和E，心脏功能分别正常和临界，停用了每日50毫克的卡格列净。EF、%FS和乙酰乙酸/β-羟基丁酸水平均下降。综上所述，这些结果表明，无论是否使用卡格列净，均可观察到酮体与心脏功能之间的伴随变化。该药物可能通过调节酮体对心脏功能产生影响。
